Book contents
- Polycystic Ovary Syndrome
- Polycystic Ovary Syndrome
- Copyright page
- Contents
- Contributors
- Chapter 1 Introduction to and History of Polycystic Ovary Syndrome
- Chapter 2 Polycystic Ovary Syndrome: From Phenotype to Genotype
- Chapter 3 The Epidemiology of Polycystic Ovary Syndrome
- Chapter 4 Ovarian Ultrasonography in Polycystic Ovary Syndrome
- Chapter 5 The Classification of Polycystic Ovary Syndrome Informed by the International Guideline 2018
- Chapter 6 The Relevance of the Anti-Müllerian Hormone in Polycystic Ovary Syndrome Diagnosis and Management
- Chapter 7 Origins of Polycystic Ovary Syndrome In Utero
- Chapter 8 Adrenal and Polycystic Ovary Syndrome
- Chapter 9 Polycystic Ovary Syndrome and Environmental Toxins
- Chapter 10 Lifestyle in Polycystic Ovary Syndrome
- Chapter 11 Ovulation Induction in Polycystic Ovary Syndrome
- Chapter 12 Ovarian Surgery for Ovulation Induction
- Chapter 13 In Vitro Fertilization and Assisted Reproductive Technologies in Polycystic Ovary Syndrome
- Chapter 14 Pregnancy Complications and Children Outcomes in Patients with Polycystic Ovarian Syndrome
- Chapter 15 The Role of In Vitro Maturation in Polycystic Ovary Syndrome
- Chapter 16 The Treatment of Obesity in Polycystic Ovary Syndrome
- Chapter 17 Mood Disorders in Polycystic Ovary Syndrome
- Chapter 18 The Long-Term Health Consequences of Polycystic Ovary Syndrome
- Chapter 19 Polycystic Ovary Syndrome
- Chapter 20 Cancer and Polycystic Ovary Syndrome
- Index
- References
Chapter 6 - The Relevance of the Anti-Müllerian Hormone in Polycystic Ovary Syndrome Diagnosis and Management
Published online by Cambridge University Press: 13 May 2022
- Polycystic Ovary Syndrome
- Polycystic Ovary Syndrome
- Copyright page
- Contents
- Contributors
- Chapter 1 Introduction to and History of Polycystic Ovary Syndrome
- Chapter 2 Polycystic Ovary Syndrome: From Phenotype to Genotype
- Chapter 3 The Epidemiology of Polycystic Ovary Syndrome
- Chapter 4 Ovarian Ultrasonography in Polycystic Ovary Syndrome
- Chapter 5 The Classification of Polycystic Ovary Syndrome Informed by the International Guideline 2018
- Chapter 6 The Relevance of the Anti-Müllerian Hormone in Polycystic Ovary Syndrome Diagnosis and Management
- Chapter 7 Origins of Polycystic Ovary Syndrome In Utero
- Chapter 8 Adrenal and Polycystic Ovary Syndrome
- Chapter 9 Polycystic Ovary Syndrome and Environmental Toxins
- Chapter 10 Lifestyle in Polycystic Ovary Syndrome
- Chapter 11 Ovulation Induction in Polycystic Ovary Syndrome
- Chapter 12 Ovarian Surgery for Ovulation Induction
- Chapter 13 In Vitro Fertilization and Assisted Reproductive Technologies in Polycystic Ovary Syndrome
- Chapter 14 Pregnancy Complications and Children Outcomes in Patients with Polycystic Ovarian Syndrome
- Chapter 15 The Role of In Vitro Maturation in Polycystic Ovary Syndrome
- Chapter 16 The Treatment of Obesity in Polycystic Ovary Syndrome
- Chapter 17 Mood Disorders in Polycystic Ovary Syndrome
- Chapter 18 The Long-Term Health Consequences of Polycystic Ovary Syndrome
- Chapter 19 Polycystic Ovary Syndrome
- Chapter 20 Cancer and Polycystic Ovary Syndrome
- Index
- References
Summary
Anti-Müllerian hormone (AMH) has recently been proposed as a diagnostic marker for polycystic ovary syndrome (PCOS) instead of polycystic ovarian morphology (PCOM) seen on ultrasound. As serum AMH level reflects excess small follicles not visible on ultrasonography, AMH level would theoretically be more accurate than PCOM as a diagnostic marker. Its value is significantly higher in PCOS patients than in normal women; its high levels are also considered to play an important role in the pathogenesis of the disorder, accounting for anovulation in PCOS patients. Nevertheless, its use is still not recommended by the international guidelines as an alternative for detecting PCOM or as a single test result for the diagnosis of PCOS. Its potential clinical applications in PCOS patients are currently the characterization of the severity of the syndrome and in deciding hormone doses for ovarian stimulation treatments. An international standard is needed to standardize the existing assays for AMH calibration before diagnostic cutoffs can be determined and before AMH use as a diagnostic marker can be considered meaningful.
Keywords
- Type
- Chapter
- Information
- Polycystic Ovary Syndrome , pp. 52 - 57Publisher: Cambridge University PressPrint publication year: 2022